Abstract
Skeletal muscle insulin resistance is a hallmark feature of Type 2 diabetes. Physical exercise/muscle contraction elicits an insulin-independent increase in glucose transport and perturbation of this pathway may bypass defective insulin signaling. To date, the exercise-responsive signaling molecules governing glucose metabolism in skeletal muscle are largely unknown. AMPactivated protein kinase (AMPK) has been suggested as one of the exercise-responsive signaling molecules involved in glucose homeostasis and consequently it has been heavily explored as a pharmacological target for the treatment of Type 2 diabetes. AMPK exists in heterotrimeric complexes composed of a catalytic α-subunit and regulatory β- and γ-subunits. The γ3-isoform of AMPK is expressed specifically in skeletal muscle of humans and rodents and this tissue specific expression pattern offers selectivity in AMPK action. Furthermore, mutations in the AMPK γ3-isoform may provide protection from diet-induced insulin resistance by increasing lipid oxidation in the presence of increased lipid supply. This review highlights the current understanding of the role of the regulatory AMPK γ3-isoform in the control of skeletal muscle metabolism.
Keywords: skeletal muscle, amp-activated protein kinase, exercise, type diabetes, insulin resistance, metabolism
Current Molecular Medicine
Title: Role of AMP-Activated Protein Kinase in the Control of Glucose Homeostasis
Volume: 5 Issue: 3
Author(s): B. R. Barnes and J. R. Zierath
Affiliation:
Keywords: skeletal muscle, amp-activated protein kinase, exercise, type diabetes, insulin resistance, metabolism
Abstract: Skeletal muscle insulin resistance is a hallmark feature of Type 2 diabetes. Physical exercise/muscle contraction elicits an insulin-independent increase in glucose transport and perturbation of this pathway may bypass defective insulin signaling. To date, the exercise-responsive signaling molecules governing glucose metabolism in skeletal muscle are largely unknown. AMPactivated protein kinase (AMPK) has been suggested as one of the exercise-responsive signaling molecules involved in glucose homeostasis and consequently it has been heavily explored as a pharmacological target for the treatment of Type 2 diabetes. AMPK exists in heterotrimeric complexes composed of a catalytic α-subunit and regulatory β- and γ-subunits. The γ3-isoform of AMPK is expressed specifically in skeletal muscle of humans and rodents and this tissue specific expression pattern offers selectivity in AMPK action. Furthermore, mutations in the AMPK γ3-isoform may provide protection from diet-induced insulin resistance by increasing lipid oxidation in the presence of increased lipid supply. This review highlights the current understanding of the role of the regulatory AMPK γ3-isoform in the control of skeletal muscle metabolism.
Export Options
About this article
Cite this article as:
Barnes R. B. and Zierath R. J., Role of AMP-Activated Protein Kinase in the Control of Glucose Homeostasis, Current Molecular Medicine 2005; 5 (3) . https://dx.doi.org/10.2174/1566524053766103
DOI https://dx.doi.org/10.2174/1566524053766103 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy Insulin Regulation of PEPCK Gene Expression: A Model for Rapid and Reversible Modulation
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Regulation of Neuroimmune-Endocrine Interactions: Mechanisms,Molecular Pathways Unraveled and the Pivotal Role of Cytokines – A Unsung Putative Bidirectional Interdependence between the Immune and Neuroendocrine Interfaces
Current Immunology Reviews (Discontinued) Quantum Dots as Promising Theranostic Tools Against Amyloidosis: A Review
Protein & Peptide Letters Patent Selections
Recent Patents on Drug Delivery & Formulation Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Receptor Proteins for Nongenomic Actions of Thyroid Hormone
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting Small Arteries of Hypertensive Status with Novel ATP-Sensitive Potassium Channel Openers&#
Current Vascular Pharmacology The Anti-inflammatory Potential of Selected Plant-derived Compounds in Respiratory Diseases
Current Pharmaceutical Design Bacterial Recognition and Induced Cell Activation in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Targets Involved in Cardioprotection by the Non-Anesthetic Noble Gas Helium
Current Drug Targets Sigma-1 Receptor Chaperones and Diseases
Central Nervous System Agents in Medicinal Chemistry Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management
Current Pharmaceutical Design Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Activity-Based Proteomics of Lipolytic Enzymes
Current Drug Discovery Technologies Patent Selections
Recent Patents on Drug Delivery & Formulation Na+/Ca2+ Exchange Inhibitors: A New Class of Calcium Regulators
Cardiovascular & Hematological Disorders-Drug Targets